Gawrieh S, Noureddin M, Loo N, et al. - A randomized controlled clinical trial was designed to investigate the efficacy and safety of saroglitazar in patients with NAFLD/NASH. Researchers randomized a total of 106 patients with NAFLD/NASH with alanine aminotransferase (ALT) ≥ 50 U/L at baseline and body mass index ≥ 25 kg/m2 in a 1:1:1:1 ratio to receive placebo or saroglitazar 1 mg, 2 mg, or 4 mg for 16 weeks. As per the findings, ALT, LFC, insulin resistance, and atherogenic dyslipidemia were significantly improved by saroglitazar 4 mg in participants with NAFLD/NASH.